Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mucolox and Clonazepam for Burning Mouth Syndrome
NCT02690844Phase 4Withdrawn
- Sponsor
- University of Alberta
- Start
- Apr 2016
- Primary completion
- May 2016
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of clonazepam in burning mouth syndrome (BMS), sponsored by University of Alberta. Planned start Apr 2016; status: withdrawn.
02
Drugs
clonazepam
03
Conditions
burning mouth syndrome (BMS)
Beyond the preview
Go deeper on NCT02690844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02690844.